Interferon gamma producing blood lymphocytes are decreased by interferon beta therapy in patients with multiple sclerosis

被引:23
作者
Petereit, HF
Bamborschke, S
Esse, AD
Heiss, WD
机构
[1] Klin./Poliklin. Neurol./P.N.M.E., Universität zu Köln
来源
MULTIPLE SCLEROSIS | 1997年 / 3卷 / 03期
关键词
multiple sclerosis; interferon beta therapy; interferon gamma; immunomodulatory therapy; indicator of therapeutical effectiveness;
D O I
10.1177/135245859700300302
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: We studied the individual course of interferon gamma producing blood lymphocyte count (IFGC) of 15 multiple sclerosis patients started on 8 MIU beta interferon administered subcutaneously each other day Methods: Mononuclear blood cells were prepared before treatment and on day 3, 9, 15, as well as after month 1, 2, 3 and 4 of therapy. After stimulation intracellular interferon gamma was detected with monoclonal fluorescent antibodies and measured by flowcytometry. IFGC is given as percentage of oil gated lymphocytes. Results: forty-eight hours after first interferon beta application the mean IFGC dropped significantly from 11.37 to 7.09 (P < 0.05) and to 4.22 within 4 months. Whereas the majority of patients showed a decrease of IFGC from the beginning of therapy in three of the 15 patients a transient increase of IFGC was seen suggesting a different response to immunomodulatory therapy. Conclusions: Interferon gamma producing lymphocyte count might be a useful tool to determine the biological effect of interferon beta therapy in multiple sclerosis patients.
引用
收藏
页码:180 / 183
页数:4
相关论文
共 34 条
[1]   INTERFERON-BETA IN MULTIPLE-SCLEROSIS [J].
ARNASON, BGW .
NEUROLOGY, 1993, 43 (04) :641-643
[2]   CORTICOSTEROID INHIBITION OF THE OKT3-INDUCED CYTOKINE-RELATED SYNDROME - DOSAGE AND KINETICS PREREQUISITES [J].
CHATENOUD, L ;
LEGENDRE, C ;
FERRAN, C ;
BACH, JF ;
KREIS, H .
TRANSPLANTATION, 1991, 51 (02) :334-338
[3]   Interferon-gamma-secreting cells in multiple sclerosis patients treated with interferon beta-1b [J].
Dayal, AS ;
Jensen, MA ;
Lledo, A ;
Arnason, BGW .
NEUROLOGY, 1995, 45 (12) :2173-2177
[4]  
ELLAURIE M, 1991, ANN ALLERGY, V66, P143
[5]  
FIERLBECK G, 1994, CANCER IMMUNOL IMMUN, V39, P263, DOI 10.1007/BF01525990
[6]   HUMAN BIOLOGIC RESPONSE MODIFICATION BY INTERFERON IN THE ABSENCE OF MEASURABLE SERUM CONCENTRATIONS - A COMPARATIVE TRIAL OF SUBCUTANEOUS AND INTRAVENOUS INTERFERON-BETA SERINE [J].
GOLDSTEIN, D ;
SIELAFF, KM ;
STORER, BE ;
BROWN, RR ;
DATTA, SP ;
WITT, PL ;
TEITELBAUM, AP ;
SMALLEY, RV ;
BORDEN, EC .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1989, 81 (14) :1061-1068
[7]   LYMPHOCYTES FROM MULTIPLE-SCLEROSIS PATIENTS PRODUCE ELEVATED LEVELS OF GAMMA-INTERFERON INVITRO [J].
HIRSCH, RL ;
PANITCH, HS ;
JOHNSON, KP .
JOURNAL OF CLINICAL IMMUNOLOGY, 1985, 5 (06) :386-389
[8]   IFN-ALPHA INDUCED HUMAN 78-KD PROTEIN - PURIFICATION AND HOMOLOGIES WITH THE MOUSE MX PROTEIN, PRODUCTION OF MONOCLONAL-ANTIBODIES, AND POTENTIATION EFFECT OF IFN-GAMMA [J].
HORISBERGER, MA ;
HOCHKEPPEL, HK .
JOURNAL OF INTERFERON RESEARCH, 1987, 7 (04) :331-343
[9]   IMMUNE-RESPONSE ASSOCIATED PRODUCTION OF NEOPTERIN - RELEASE FROM MACROPHAGES PRIMARILY UNDER CONTROL OF INTERFERON-GAMMA [J].
HUBER, C ;
BATCHELOR, JR ;
FUCHS, D ;
HAUSEN, A ;
LANG, A ;
NIEDERWIESER, D ;
REIBNEGGER, G ;
SWETLY, P ;
TROPPMAIR, J ;
WACHTER, H .
JOURNAL OF EXPERIMENTAL MEDICINE, 1984, 160 (01) :310-316
[10]   INTRAVENOUS NATURAL BETA-INTERFERON TREATMENT OF CHRONIC EXACERBATING-REMITTING MULTIPLE-SCLEROSIS - CLINICAL-RESPONSE AND MRI CSF FINDINGS [J].
HUBER, M ;
BAMBORSCHKE, S ;
ASSHEUER, J ;
HEISS, WD .
JOURNAL OF NEUROLOGY, 1988, 235 (03) :171-173